Research Suggests That Cardiac Marker NT-proBNP is a Better Predictor for Mortality Than BNP in Heart Failure Patients with Reduced Kidney Function.DEERFIELD, Ill. -- Dade Behring Inc.(NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DADE) today announced that research presented at the American Heart Association's Scientific Sessions 2005 in Dallas, Texas, suggests that the cardiac marker NT-proBNP (N-terminal pro brain natriuretic peptide Brain natriuretic peptide (also known as B-type natriuretic peptide or "GC-B") is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of myocytes (heart muscles cells) in the ventricles. ) is a better predictor for mortality in heart failure patients than BNP BNP B-type natriuretic peptide, brain natriuretic peptide Physiology A 32-residue peptide hormone produced predominantly in the ventricles, secreted in response to fluid overload–eg, CHF. See Atrial natriuretic peptide. (brain natriuretic peptide), regardless of kidney function. The research also shows that NT-proBNP is a prognostic tool for heart failure patients, in addition to being a diagnostic tool. Heart failure is often difficult to diagnose, since its symptoms are sometimes confused with those of other conditions such as chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. . Among the abstracts presented at the American Heart Association's Scientific Sessions were the following: --Combining NT-proBNP and Glomerular Filtration Rate glomerular filtration rate n. Abbr. GFR The volume of water filtered out of the plasma through glomerular capillary walls into Bowman's capsules per unit of time. (GFR) to Predict Prognosis in Patients with Heart Failure: An Analysis from the International Collaborative of NT-proBNP (ICON) Study(1), R.R.J. van Kimmenade, et al. The study concluded that elevated NT-proBNP concentration in the presence of a low GFR strongly predicts 60-day mortality in patients with acute congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. (CHF), better than either individual parameter alone; 60-day survival was similar in patients with either a low GFR or a high NT-proBNP. The authors concluded that this argues against the notion that NT-proBNP is artifactually elevated by impaired GFR. The study included a pooled analysis of 1,256 dyspneic patients. --Concomitant Kidney Disease and Heart Failure: Diagnostic and Prognostic Utility of N-terminal proBNP and B-type Natriuretic Peptide B-type natriuretic peptide See BNP. (2), C.deFilippi, et al. The study concluded that NT-proBNP and BNP have similar accuracy for predicting decompensated heart failure (DHF) in patients, regardless of kidney function. However, NT-proBNP is a better predictor of mortality irrespective of kidney disease (KD). Elevated NT-proBNP levels in KD patients frequently indicate underlying cardiac pathology. The study measured NT-proBNP and BNP in 904 patients, 423 with a GFR less than 60mL/min/1.73m(2). --Application of N-terminal ProBNP and B-type Natriuretic Peptide in a Large Community Cohort: Similarities and Differences for Diagnosing Heart Failure and Predicting Mortality(3), R.H. Christenson, et al. The authors conclude that NT-proBNP and BNP demonstrated similar performance for diagnosing decompensated heart failure, but that NT-proBNP level is a significantly better predictor of long-term all-cause mortality than BNP, perhaps reflecting the ability to detect cardiac pathology other than DHF. The study measured NT-proBNP and BNP in 904 patients. About Dade Behring With 2004 revenues of nearly $1.6 billion, Dade Behring is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of labs, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the internet at www.dadebehring.com. 1. Roland R van Kimmenade, Jaap A Bakker, Alfons J Houben, Abraham A Kroon kroon n. pl. kroon·i See Table at currency. [Estonian, from German Krone, from Middle High German kr , Roger Rennenberg, Harry J Crijns, Marja P van Dieijen-Visser, Peter W de Leeuw, Yigal M Pinto, University Hospital Maastricht, Maastricht, The Netherlands. Renal Handling of BNP and NT-proBNP in Hypertensive Subjects. (AHA 2005; abstract 2843/C165) 2. Christopher deFilippi, University of Maryland, Baltimore University of Maryland, Baltimore, (also known as UMB) was founded in 1807. It is one of the oldest universities in the United States and comprises some of the oldest professional schools in the nation and world. , MD; Susan Maynard, Carolinas Medical Center Carolinas Medical Center (CMC) is a public, not for profit hospital located in Charlotte, North Carolina. The hospital was organized in 1940 as Charlotte Memorial Hospital on Blythe Boulevard in the Dilworth neighborhood. , Charlotte, NC; Ruby C Dunston, Strelitzia R Tjon Kon Fat, Show-Hong Duh, Hegang Chen, Abel Joy, Cindy N Bowen, Robert H Christenson, University of Maryland, Baltimore, MD. Concomitant Kidney Disease and Heart Failure: Diagnostic and Prognostic Utility of N-terminal proBNP and B-type Natriuretic Peptide. (AHA 2005; abstract 2838/C160) 3. Robert H Christenson, University of Maryland University of Maryland can refer to:
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion